

Japan's GHIT strengthens ties with Unitaaid to improve access to critical health tools

02 March 2023 | News

To focus on tackling complex challenges such as emerging drug resistance in tuberculosis



The Global Health Innovative Technology Fund (GHIT Fund) and global health agency Unitaaid have signed a cooperation framework that aims to strengthen collaboration between the two agencies to increase cooperation between the Japanese research and development industry and the broader global health response. The partnership will focus on tackling complex challenges such as emerging drug resistance in tuberculosis (TB) and malaria and shifting patterns of vector-borne diseases due to climate change.

By reinforcing links between the GHIT Fund's research and development pipeline and Unitaaid's expertise in product introduction and access, the framework will further efforts to connect partners and ideas dealing with topics of health innovation, access, and scale.

The agreement unites the two agencies at a broad strategic level and creates a channel for continuous collaboration, scanning the innovation pipeline for late-stage products that address the most pressing global health needs. This work will further efforts to ensure vulnerable and underserved populations have access to better health products and support progress towards universal health coverage.

The GHIT Fund is a Japan-based international public-private partnership (PPP) fund that was formed between the Government of Japan, multiple pharmaceutical companies, the Bill & Melinda Gates Foundation, Wellcome, and the United Nations Development Programme (UNDP). The GHIT Fund invests and manages an R&D portfolio of development partnerships aimed at addressing neglected diseases such as malaria, tuberculosis, and neglected tropical diseases that afflict the world's vulnerable and underserved populations.